

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://fdi-lab.sci-crunch.org) on Apr 30, 2024

InVivoPlus anti-mouse IFN?

RRID:AB_1107694

Type: Antibody

Proper Citation

(Bio X Cell Cat# BE0055 (also BE0055-100MG, BE0055-1MG, BE0055-25MG, BE0055-50MG, BE0055-5MG, BP0055-100MG, BP0055-25MG, BP0055-50MG, BP0055-5MG), RRID:AB_1107694)

Antibody Information

URL: http://antibodyregistry.org/AB_1107694

Proper Citation: (Bio X Cell Cat# BE0055 (also BE0055-100MG, BE0055-1MG, BE0055-25MG, BE0055-50MG, BE0055-5MG, BP0055-100MG, BP0055-25MG, BP0055-50MG, BP0055-5MG), RRID:AB_1107694)

Target Antigen: IFN?

Host Organism: rat

Clonality: monoclonal

Comments: Applications: in vivo IFN? neutralization, in vitro IFN? neutralization, ELISPOT, Flow cytometry

Consolidation on 12/2021: AB_1107694, AB_2894796.

Antibody Name: InVivoPlus anti-mouse IFN?

Description: This monoclonal targets IFN?

Target Organism: mouse

Clone ID: clone XMG1.2

Antibody ID: AB_1107694

Vendor: Bio X Cell

Catalog Number: BE0055 (also BE0055-100MG, BE0055-1MG, BE0055-25MG, BE0055-50MG, BE0055-5MG, BP0055-100MG, BP0055-25MG, BP0055-50MG, BP0055-5MG)

Alternative Catalog Numbers: BE0055-50MG, BE0055-100MG, BE0055-5MG, BP0055-50MG, BE0055-1MG, BP0055-100MG, BP0055-5MG, BE0055-25MG, BP0055-25MG

Ratings and Alerts

No rating or validation information has been found for InVivoPlus anti-mouse IFN?

No alerts have been found for InVivoPlus anti-mouse IFN?.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 87 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Englebert K, et al. (2024) The CD27/CD70 pathway negatively regulates visceral adipose tissue-resident Th2 cells and controls metabolic homeostasis. Cell reports, 43(3), 113824.

Kwon DI, et al. (2024) Fc-fused IL-7 provides broad antiviral effects against respiratory virus infections through IL-17A-producing pulmonary innate-like T cells. Cell reports. Medicine, 5(1), 101362.

Beck JD, et al. (2024) Long-lasting mRNA-encoded interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers. Cancer cell.

Shapir Itai Y, et al. (2024) Bispecific dendritic-T cell engager potentiates anti-tumor immunity. Cell, 187(2), 375.

Xue G, et al. (2024) Clinical drug screening reveals clofazimine potentiates the efficacy while reducing the toxicity of anti-PD-1 and CTLA-4 immunotherapy. Cancer cell.

Tibbs TN, et al. (2023) Mice with FVB-derived sequence on chromosome 17 succumb to disseminated virus infection due to aberrant NK cell and T cell responses. iScience, 26(11), 108348.

Tichet M, et al. (2023) Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8+ T cells and reprogramming macrophages. Immunity, 56(1), 162.

Kong X, et al. (2023) Type I interferon/STAT1 signaling regulates UBE2M-mediated antiviral innate immunity in a negative feedback manner. *Cell reports*, 42(1), 112002.

Bailey C, et al. (2023) Genetic and pharmaceutical targeting of HIF1 α allows combination immunotherapy to boost graft vs. leukemia without exacerbation graft vs. host disease. *Cell reports. Medicine*, 4(11), 101236.

Tsai CH, et al. (2023) Immunoediting instructs tumor metabolic reprogramming to support immune evasion. *Cell metabolism*, 35(1), 118.

Zhu Y, et al. (2023) Opioid-induced fragile-like regulatory T cells contribute to withdrawal. *Cell*, 186(3), 591.

Gungabeesoon J, et al. (2023) A neutrophil response linked to tumor control in immunotherapy. *Cell*, 186(7), 1448.

Garofalo S, et al. (2023) Natural killer cells and innate lymphoid cells 1 tune anxiety-like behavior and memory in mice via interferon- γ and acetylcholine. *Nature communications*, 14(1), 3103.

Gong M, et al. (2023) Transcriptional and metabolic programs promote the expansion of follicular helper T cells in lupus-prone mice. *iScience*, 26(5), 106774.

Yadav N, et al. (2023) More time to kill: A longer liver stage increases T cell-mediated protection against pre-erythrocytic malaria. *iScience*, 26(12), 108489.

Chandra A, et al. (2023) Quantitative control of Ets1 dosage by a multi-enhancer hub promotes Th1 cell differentiation and protects from allergic inflammation. *Immunity*, 56(7), 1451.

Earley ZM, et al. (2023) GATA4 controls regionalization of tissue immunity and commensal-driven immunopathology. *Immunity*, 56(1), 43.

Olivera I, et al. (2023) mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy. *Cell reports. Medicine*, 4(3), 100978.

Cui K, et al. (2023) Restraint of IFN- γ expression through a distal silencer CNS-28 for tissue homeostasis. *Immunity*, 56(5), 944.

Ma L, et al. (2023) Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. *Cell*, 186(15), 3148.